Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine

Journal of Clinical Virology

Volumn 31, Issue 3, 2004, Pages 198-203

  Uhlmann, Erik J ^a   Tebas, Pablo ^a   Storch, Gregory A ^a   Powderly, William G ^a   Lie, Yolanda S ^b   Whitcomb, Jeannette M ^b   Hellmann, Nicholas S ^b   Arens, Max Q ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MONOGRAM BIOSCIENCES   (United States)

Author keywords

Delavirdine sensitivity; HIV; HIV G190A mutation; human immunodeficiency virus; NNRTI; NNRTI resistance; Non nucleoside reverse transcriptase inhibitor; NRTI; Nucleoside reverse transcriptase inhibitor; Reverse transcriptase polymerase chain reaction; RT PCR

Indexed keywords

DELAVIRDINE; EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS ENZYME;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG SENSITIVITY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KRUSKAL WALLIS TEST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RANK SUM TEST; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE;

ANTI-HIV AGENTS; DELAVIRDINE; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 4744350818     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2004.03.012     Document Type: Article

References (35)

1. Bacheler L., Jeffrey S., Hanna G., D'Aquila R., Wallace L., Logue K., et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J. Virol. 75:2001;4999-5008
2. Bacolla A., Shih C.K., Rose J.M., Piras G., Warren T.C., Grygon C.A., et al. Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2. Effect on kinetic constants and inhibition by non-nucleoside analogs. J. Biol. Chem. 268:1993;16571-16577
3. Boden D., Hurley A., Zhang L., Cao Y., Guo Y., Jones E., et al. HIV-1 drug resistance in newly infected individuals. JAMA. 282:1999;1135-1141
4. Boyer P.L., Gao H.Q., Hughes S.H. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer. Antimicrob. Agents Chemother. 42:1998;447-452
5. Casado J.L., Hertogs K., Ruiz L., Dronda F., Van Cauwenberge A., Arno A., et al. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. AIDS. 14:2000;F1-F7
6. Clevenbergh P., Cua E., Dam E., Durant J., Schmit J.C., Boulme R., et al. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients. HIV Clin. Trials. 3:2002;36-44
7. Davey R.T. Jr., Chaitt D.G., Reed G.F., Freimuth W.W., Herpin B.R., Metcalf J.A., et al. Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 40:1996;1657-1664
8. Demeter L.M., Shafer R.W., Meehan P.M., Holden-Wiltse J., Fischl M.A., Freimuth W.W., et al. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob. Agents Chemother. 44:2000;794-797
9. Dueweke T.J., Pushkarskaya T., Poppe S.M., Swaney S.M., Zhao J.Q., Chen I.S., et al. A mutation in reverse transcriptase of bis(heteroaryl)piperazine- resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. U.S.A. 90:1993;4713-4717
10. Dykes C., Fox K., Lloyd A., Chiulli M., Morse E., Demeter L.M. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. Virology. 285:2001;193-203
11. Esnouf R.M., Ren J., Hopkins A.L., Ross C.K., Jones E.Y., Stammers D.K., et al. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc. Natl. Acad. Sci. U.S.A. 94:1997;3984-3989
12. Fan N., Evans D.B., Rank K.B., Thomas R.C., Tarpley W.G., Sharma S.K. Mechanism of resistance to U-90152S and sensitization to L-697, 661 by a proline to leucine change at residue 236 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. FEBS Lett. 359:1995a;233-238
13. Fan N., Rank K.B., Evans D.B., Thomas R.C., Tarpley W.G., Sharma S.K. Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s. FEBS Lett. 370:1995;59-62
14. Fan N., Rank K.B., Slade D.E., Poppe S.M., Evans D.B., Kopta L.A., et al. A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation. Biochemistry. 35:1996;9737-9745
15. Fujiwara T., Sato A., el-Farrash M., Miki S., Abe K., Isaka Y., et al. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 42:1998;1340-1345
16. Gazzard B., Moyle G. 1998 Revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet. 352:1998;314-316
17. Gerondelis P., Archer R.H., Palaniappan C., Reichman R.C., Fay P.J., Bambara R.A., et al. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end- and DNA 3′-end-directed RNase H activities. J. Virol. 73:1999;5803-5813
18. Ho D.D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 12:1995;123-126
19. Huang W., Gamarnik A., Limoli K., Petropoulos C.J., Whitcomb J.M. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J. Virol. 77:2003;1512-1523
20. Isaka Y., Miki S., Kawauchi S., Suyama A., Sugimoto H., Adachi A., et al. A single amino acid change at Leu-188 in the reverse transcriptase of HIV-2 and SIV renders them sensitive to non-nucleoside reverse transcriptase inhibitors. Arch. Virol. 146:2001;743-755
21. Joly V., Moroni M., Concia E., Lazzarin A., Hirschel B., Jost J., et al. The M/331/0013B Study Group. Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. Antimicrob. Agents Chemother. 44:2000;3155-3157
22. Kleim J.P., Bender R., Kirsch R., Meichsner C., Paessens A., Riess G. Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase. Virology. 200:1994;696-701
23. Little S.J., Daar E.S., D'Aquila R.T., Keiser P.H., Connick E., Whitcomb J.M., et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA. 282:1999;1142-1149
24. Loya S., Bakhanashvili M., Tal R., Hughes S.H., Boyer P.L., Hizi A. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-isoleucine and tyrosine 188-leucine), resistant to non-nucleoside inhibitors. AIDS Res. Hum. Retroviruses. 10:1994;939-946
25. Montaner J.S.G., Shillington A., Montaner L.J.G. HIV/AIDS treatment - lessons from the tuberculosis experience. Drug Resist. Updat. 1:1998;157-160
26. Olmsted R.A., Slade D.E., Kopta L.A., Poppe S.M., Poel T.J., Newport S.W., et al. (Alkylamino)piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum non-nucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes. J. Virol. 70:1996;3698-3705
27. Pelemans H., Esnouf R., Dunkler A., Parniak M.A., Vandamme A.M., Karlsson A., et al. Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1. J. Virol. 71:1997;8195-8203
28. Pelemans H., Esnouf R.M., Parniak M.A., Vandamme A.M., De Clercq E., Balzarini J. A proline-to-histidine substitution at position 225 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitizes HIV-1 RT to BHAP U-90152. J. Gen. Virol. 79:1998;1347-1352
29. Petropoulos C.J., Parkin N.T., Limoli K.L., Lie Y.S., Wrin T., Huang W., et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:2000;920-928
30. Shafer R.W. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin. Microbiol. Rev. 15:2002;247-277
31. Shih C.K., Rose J.M., Hansen G.L., Wu J.C., Bacolla A., Griffin J.A. Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to non-nucleoside analog inhibitors. Proc. Natl. Acad. Sci. U.S.A. 88:1991;9878-9882
32. Shulman N., Zolopa A.R., Passaro D., Shafer R.W., Huang W., Katzenstein D., et al. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS. 15:2001;1125-1132
33. Smerdon S.J., Jager J., Wang J., Kohlstaedt L.A., Chirino A.J., Friedman J.M., et al. Structure of the binding site for non-nucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 91:1994;3911-3915
34. Wei X., Ghosh S.K., Taylor M.E., Johnsos V.A., Emini E.A., Deutsch P., et al. Viral dynamics in human immunodeficiency type 1 infection. Nature. 12:1995;117-122
35. Witvrouw M., Pannecouque C., Van Laethem K., Desmyter J., De Clercq E., Vandamme A.M. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS. 13:1999;1477-1483